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In its review of hormonally active agents in
the environment, the National Research
Council (NRC 1999) recommended that fur-
ther investigations of human exposure to nat-
ural and anthropogenic hormonally active
agents be conducted to determine relative
contributions of estrogen equivalents. The
NRC (1999, p. 273) further recommended
that the 
biological potency of hormonally active agents
must be related to that of endogenous hormones
in premenopausal and postmenopausal women
and in men. Additional comparisons should be
made with pharmacologic estrogens (hormone-
replacement therapy and hormonal contra-
ceptives) and phytoestrogens because large
segments of the population are exposed to these
compounds.
In addition, the Endocrine Disruptor
Screening and Testing Advisory Committee
recommended that the U.S. Environmental
Protection Agency (U.S. EPA) screen and
potentially test “representative mixtures to
which large . . . segments of the population
are exposed,” including human milk
(EDSTAC 1998), which has raised questions
regarding whether appropriate methods and
data are available for performing such an
assessment (LaKind and Berlin 2002).
The assessment implied by the recommen-
dations of those scientiﬁc bodies would involve
using biological mechanistic information
coupled with exposure data to assess overall
human health risk for a particular mechanism.
This concept is not new and has been used,
for example, to evaluate risks to dioxin-like
chemicals that are presumed or demonstrated
to act through an aryl hydrocarbon (Ah)
receptor–mediated mechanism (i.e., the toxic
equivalents, or TEQ, approach). Similarly,
Safe (1995) and NRC (1999) have compared
the toxic potency of dietary and environmen-
tal estrogenic chemicals, using the concept of
estrogen equivalents (EQs) where the sub-
stances are presumed to act though an estro-
gen receptor (ER)–mediated mechanism. On
the basis of the EQ approach, Safe (1995)
estimated that dietary intake of EQs from nat-
urally occurring estrogenic compounds far
exceeds dietary intake of man-made estrogenic
compounds.
In an extension of this approach, we
initially sought to apply methods for estimat-
ing relative estrogenic potencies of endogenous
and exogenous chemicals to assessing estro-
genic risks for the two primary sources of
infant nutrition: human milk and infant
formulas. Both types of infant nutrition are
complex mixtures of chemicals, and both
contain an array of substances that have poten-
tial estrogenic activity. In combination with
information on concentrations of endogenous
and exogenous chemicals in these nutrition
sources, estrogenic potency estimates would
theoretically allow us to evaluate the relative
magnitude of hormonal activity from naturally
occurring substances compared with hormonal
activity from exogenous substances. However,
for reasons enumerated in this review, we
believe that the current state of scientific
understanding does not allow for accurate esti-
mates by such methods. Although we recog-
nize that hormonally active agents encompass a
wide range of biochemical mechanisms, the
focus of this paper is estrogenicity, because it is
the hormonal mechanism for which most
information exists.
To explain our conclusion, we ﬁrst provide
a review of endogenous hormones and exo-
genous chemicals found in human milk that
have been reported to be hormonally active,
particularly those that are known, suspected, or
purported to act through the ER. Second, we
review the phytoestrogens and other hormon-
ally active agents found in certain infant for-
mulas. Third, we examine the mechanisms of
estrogen action and various types of in vivo
and in vitro assays used to measure estrogenic
potency and biologic effects. We close with a
review and analysis of methods to assess the
potency of estrogenic mixtures that could be
used in the evaluation of human milk and for-
mula. Because the goal of such an analysis is to
predict whether hormonally active agents in
infant nutritional sources are related to adverse
health outcomes, we also summarize the epi-
demiologic and clinical literature on associa-
tions between infant exposures to hormonally
active chemicals and health outcomes, and
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The two primary sources of nutrition for infants are human milk and infant formula. Both contain
an array of endogenous and exogenous chemicals that may act through many separate hormonal
mechanisms. The safety of infant nutrition sources has been questioned based on the possibility that
exogenous chemicals may exert adverse effects on nursing or formula-fed infants through estrogen-
mediated mechanisms. In response to these and other concerns, the National Research Council rec-
ommended assessing the estrogenic potency of natural and anthropogenic hormonally active agents.
Furthermore, the Endocrine Disruptor Screening and Testing Advisory Committee of the U.S.
Environmental Protection Agency speciﬁcally recommended testing chemicals present in human
milk as a representative mixture to which large segments of the population are exposed. To date, no
clinical or epidemiologic evidence demonstrates that levels of chemicals currently found in human
milk or infant formulas cause adverse effects in infants. Nonetheless, the question is sufﬁciently
important to warrant a consideration of how best to evaluate potential estrogenic risks. We
reviewed the types of data available for measuring estrogenic potency as well as methods for esti-
mating health risks from mixtures of chemicals in infant nutrition sources that act via estrogenic
mechanisms. We conclude that the science is insufﬁciently developed at this time to allow a credi-
ble assessment of health risks to infants based on estimates of estrogenic potency or on an under-
standing of toxicologic effects mediated by estrogenic mechanisms. However, clinical and
epidemiologic data for infant nutrition sources may provide insights about risks of such substances
in human milk and infant formulas. Key words: chemical mixtures, children’s health, cumulative
risk, endocrine disruptors, environmental estrogen, human milk, risk assessment, toxicity equiva-
lence factors. Environ Health Perspect 111:1020–1036 (2003). doi:10.1289/ehp.6023 available via
http://dx.doi.org/ [Online 25 February 2003]
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Research | Reviewidentify data gaps in the literature that might
deﬁne future research needs. We conclude that
the clinical and epidemiologic data for infant
nutrition sources are currently the most reliable
source of information regarding potential
adverse health outcomes and provide a sufﬁ-
cient basis for drawing conclusions about risks
to infants.
Endogenous Hormones 
in Human Milk
The improved ability to measure accurately a
wide range of substances in human milk has
led to the detection of a greater number of
hormones, including both nonpeptide hor-
mones such as thyroxine (T4) and hormonally
active peptides/proteins like prolactin and
somatostatin (Koldovsky 1995; Koldovsky
and Strbák 1995). Types and levels of hor-
mones in milk have been reviewed previously
(Britton and Kastin 1991; Grosvenor et al.
1992; Hamosh 2001; Koldovsky 1995;
Lawrence and Lawrence 1999). Human milk
contains pituitary, hypothalamic, pancreatic,
thyroid, parathyroid, adrenal, gonadal, and
gut hormones, sometimes in concentrations
exceeding maternal plasma levels (Ebrahim
1996; Grosvenor et al. 1992). There is evi-
dence that many hormones are absorbed by
the gut of the neonate into the neonatal circu-
lation and have important functions in the
neonate (Grosvenor et al. 1992). However,
whereas much is known about the function of
hormones in the infant (Bernt and Walker
1999; Koldovsky 1995) (e.g., the positive
inﬂuence of cortisol, an adrenal hormone, on
the maturation of the immature intestinal
barrier), in many cases the exact function of
hormones in the infant is unknown.
Hormones reported in human milk are
summarized in Table 1. Some of these hor-
mones are transported into milk from mater-
nal circulation unchanged in structure, others
are modified, and several are not only trans-
ported into the milk but are produced within
the mammary gland (Ebrahim 1996; Hamosh
2001). It has been suggested that this large
number and variety of hormones establishes
the mammary gland as a major endocrine
organ (Ebrahim 1996).
In assessing the levels of endogenous hor-
mones in human milk, an additional layer of
complexity is added when one considers that
concentrations of many hormones in human
milk change over time (Hamosh 2001). For
example, concentrations of estrogens in human
milk vary over the course of the day and during
lactation, with levels decreasing during the
first 5 days postpartum and then remaining
somewhat steady until 6 weeks postpartum
(Grosvenor et al. 1992). Concentrations of
other hormones such as insulin are highest in
colostrum and decrease with progressive lacta-
tion (Britton and Kastin 1991). Another
gonadal hormone, progesterone, is present in
milk in varying levels depending on the stage
of reproduction, decreasing considerably 24 hr
after parturition (Grosvenor et al. 1992). Milk
content of hormones could also be inﬂuenced
by circadian rhythms, number of infants previ-
ously breast-fed, and mammary gland from
which the breast milk was sampled (Britton
and Kastin 1991).
Suspected Exogenous
Estrogens in Human Milk
Exogenous substances (also called environmen-
tal chemicals) may appear in human milk if the
mother has been exposed, intentionally or
unintentionally, through various routes such as
the oral, inhalation, or dermal pathways.
Environmental chemicals that are persistent
and lipophilic can be globally dispersed and
bioaccumulate in the food chain; exposures to
these chemicals occur in most geographic loca-
tions. Other chemicals are easily metabolized
and excreted or their exposures are transient, so
their appearance in human tissues may be
more sporadic. Environmental chemicals that
are lipophilic, those that bind to milk proteins,
and others in equilibrium in the body can be
found in human milk. One of the ﬁrst studies
demonstrating that a group of environmental
chemicals—chlorinated organic chemicals—
was present in human milk was published in
1951 (Laug et al. 1951). The results showed
that human milk may contain chlorinated
organic pesticides such as DDT [trichloro-2,2-
bis(p-chlorophenyl)ethane]. Since that study
was published, many additional human milk
studies have been conducted in numerous
countries, and information on concentrations
of environmental organic chemicals in human
milk has been made available in the published
literature and government documents.
Several of the chemicals detected in
human milk have been reported to be estro-
genic—for example, certain polychlorinated
biphenyls (PCBs), DDT and its metabolites,
toxaphene, dieldrin, and lindane (Jensen and
Slorach 1991; NRC 1999). In addition, chlo-
rinated dioxins and furans have been reported
to exhibit estrogenic activity (Romkes and
Safe 1989). Although it is outside the scope of
this review to examine hormonal activity of
pharmaceuticals, clearly many of these, includ-
ing contraceptives, have the potential to inﬂu-
ence the overall hormonal activity of breast
milk; for example, there have been reports of
feminization of male infants breast-fed by
mothers using oral contraceptives (Grosvenor
et al. 1992). It should also be noted that
breast-feeding mothers consuming diets with
soy foods have higher isoﬂavone levels (conju-
gate and free) in their milk; it has been postu-
lated that this may be related to a lifetime
protective effect against cancer for the breast-
fed population (Franke and Custer 1996).
Because the data describing levels of envi-
ronmental chemicals in breast milk from
women residing in the United States are geo-
graphically limited and generally from small
populations (LaKind et al. 2001), it is likely
that human milk monitoring will be an integral
part of the planned National Children’s Study
in the United States, as well as in other smaller-
scale studies in the United States. As this body
of literature grows and methods for collecting
the information are coordinated (LaKind and
Berlin 2002), an improved description of envi-
ronmental chemicals suspected to be hormon-
ally active in the breast milk of women residing
in the United States will emerge.
Suspected Exogenous
Estrogens in Infant Formulas
Soy-based formulas account for approximately
10–20% of infant formulas purchased in the
United States (Essex 1996), with an estimated
750,000 infants fed soy-based formulas each
year (Strom et al. 2001). Infants may have
greater exposure to phytoestrogens than at any
other life stage (Whitten and Naftolin 1998).
Soy-based formulas are manufactured from
soy protein isolates (Setchell et al. 1998) and
contain the isoflavone phytoestrogens geni-
stein and daidzein, with isoﬂavone levels rang-
ing from mean values of 32 mg/L to 47 mg/L
(corresponding to an intake of approximately
6–9 mg/kg/day for an infant fed soy formula)
(Setchell et al. 1998; Whitten and Naftolin
1998). This is compared with approximately
6µ g/L isoﬂavones in human milk, or approxi-
mately 4 µg/kg/day for a breast-feeding infant
(Setchell et al. 1998; Whitten and Naftolin
1998), although levels in human milk may
increase an order of magnitude when the
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Table 1. Some hormones and their concentrations
found in human milk.a
Hormone Concentration
Pituitary
Prolactin 20–90 ng/mL
Growth hormone 5–30 µU/mL
Thyroid-stimulating hormone 2.7–5.0 µU/mL
Hypothalamus
Thyroid-releasing hormone 0.025–1.5 ng/mL
Luteinizing hormone–releasing
hormone Not available
Somatostatin 23–113 pg/mL
Gonadotropin-releasing hormone 0.1–4.0 ng/mL
Growth hormone–releasing hormone 23–430 pg/mL
Thyroid
Thyroxine (T4) 0.3–12 ng/mL
Triiodothyronine (T3) 0.2–0.4 ng/mL
Reverse T3 0.008–0.15 ng/mL
Parathyroid
Parathormone 15 pg/mL
Parathormone-related peptide 30–50 ng/mL
Calcitonin/colatonin inhibiting protein 0–5 ng/mL
Steroid
Estrogen 15–840 ng/mL
Progesterone 10–40 ng/mL
Adrenal steroids 0.2–32 ng/mL
aData from Hamosh (2001).lactating mother consumes soy food (Setchell
1996). Infants experience a high steady-state
plasma concentration of isoflavones because
of reduced intestinal biotransformation and
from daily exposure through feeding (Setchell
et al. 1998).
In addition to hormonally active agents
found in soy-based formulas, other agents may
be found in the water used to prepare the for-
mula; for example, chemicals found in streams
in the United States include surfactants, pesti-
cides, plasticizers, hormones, pharmaceuticals,
and components of personal care products
(Barnes et al. 2000; Kolpin et al. 2002). In
addition, there has been some controversy sur-
rounding the assertion that bisphenol A, which
is used to make polycarbonate baby bottles,
can leach into the formula or human milk in
the bottle (Raloff 1999).
Assessing Estrogenic Potency
The above review of hormonally active agents
in human milk and formula clearly documents
that regardless of the source of infant nutri-
tion, infants are likely to be exposed to mix-
tures of endogenous and/or exogenous
chemicals, some of which may be hormonally
active at sufficient doses. At issue is whether
exogenous chemicals contribute significantly
to the estrogenicity of these chemical mixtures
from a toxicologic or clinical standpoint. The
question of estrogenic contribution focuses on
a particular mechanism of action by which
chemicals may produce toxicity (e.g., medi-
ated by the ER) rather than on a toxic effect
per se (i.e., mediated by any one of a variety of
possible mechanisms or nonspeciﬁcally), as is
typically evaluated by human health risk
assessment methods described in guidance
from the National Research Council (NRC
1983) and the U.S. EPA (U.S. EPA 1989,
2000), the dioxin TEQ approach notwith-
standing. Toxic potency is typically evaluated
from the lowest dose that produces adverse
systemic effects or from the slope of the tumor
dose–response curve. Risk is evaluated from a
measure of exposure (or dose) and the estimate
of toxic potency.
This focus on mechanism is evident in the
NRC recommendation to compare estrogen
equivalents for exogenous chemicals and chem-
icals found naturally in foods (NRC 1999).
Comparing estrogenic equivalents as a surro-
gate for adverse effects presents a considerable
challenge to toxicologists because few assays, if
any, simultaneously provide information about
the dose–response relationship for adverse
effects and about the mechanism by which
those effects are produced. The use of biologi-
cal mechanistic information to evaluate the
potential for adverse effects has been put forth
as a useful methodology for groups of chemi-
cals whose toxicity is assumed to be produced
through a clearly deﬁned mechanism.
Before discussing the application of mech-
anistic approaches to evaluate estrogenic
potency, a very brief overview of estrogenic
action is in order. In a classical sense, the term
“estrogenic” refers to the ability of a chemical
to mimic a principal in vivo action of the hor-
mone estradiol, such as stimulating corniﬁca-
tion of the vaginal epithelium, evoking estrus
behavior or “heat” (the receptivity of a female
animal for a male), or inducing uterine en-
largement (Baird et al. 1995; Lieberman 1996;
NRC 1999). In most situations, estradiol
binds to speciﬁc ERs in estrogen-sensitive tar-
get cells where the hormone-liganded receptor
complex, on interacting with the genome,
induces transcription of specific genes and
expression of estrogen-inducible proteins. The
ER is a member of the steroid receptor family,
a discreet subgroup of the nuclear receptor
superfamily expressed in vertebrates that
includes the estrogen, androgen, progesterone,
glucocorticoid, and mineralocorticoid recep-
tors (Baker 1997; Escriva et al. 1997; Laudet
1997; Mangelsdorf et al. 1995; Thornton
2001). The structure and function of nuclear
receptors (Beato et al. 1996; Mangelsdorf et al.
1995; Tsai and O’Malley 1994; Weatherman
et al. 1999) and mechanisms of transcriptional
modulation by ERs (McKenna et al. 1999a,
1999b; Moras and Gronemeyer 1998) has
been reviewed elsewhere.
Recently it has been discovered that there
are at least two isoforms of the ER: ER-α and
ER-β. The available data indicate that these iso-
forms are differentially distributed throughout
the body, differ developmentally, and exhibit
distinct functions (Chang and Prins 1999;
Gustafsson 2000; Kuiper et al. 1996). These
molecular events lead to cell proliferation and
hypertrophy, seen physiologically as increased
mass of estrogen-sensitive organs including the
uterus and vaginal epithelium (Baird et al.
1995; Lieberman 1996; National Academy of
Sciences 1999). The increasing need to identify
large numbers of potentially estrogenic com-
pounds has led to the development of a variety
of in vitro assays based on steps within or in
close proximity to mechanisms of estrogen
action, such as binding to the ER or expression
of estrogen-responsive genes. For reasons only
partially explained to date, chemicals that inter-
act with the ER-signaling pathway can either
mimic or antagonize the actions of estradiol.
Hence, such endocrine-active chemicals—called
environmental estrogens, estrogen mimics, or
xenoestrogens—may mimic or antagonize the
action of estradiol, depending on the chemical
in question and target cell examined (Witorsch
2000, 2002).
To apply a mechanistic approach to evaluate
the estrogenic potency of infant nutrition
sources, a number of assumptions must be
made. Those assumptions include a) that hor-
monal mechanisms can be discreetly categorized
(e.g., the substance in question binds to the ER);
b) that mechanistic measures of hormonal
potency are directly related to biologic potency
and activity (i.e., that the binding afﬁnity rela-
tive to a standard is equivalent to the potency of
the substance relative to the same standard in
producing a biologic effect, such as proliferation
of cultured target cells or uterine enlargement);
and c) that mechanistic measures of hormonal
potency can be used to predict hormonal effects
of chemical mixtures. When comparing poten-
cies is intended to evaluate potential health risks,
a fourth assumption must be added: d) that the
potential for adverse effects is directly related to
mechanistic measures of hormonal potency.
The validity of these four assumptions will
determine, to a large extent, how reliably one
can compare the potential for chemicals from
various infant nutrition sources to produce
adverse effects via an estrogenic mechanism. To
evaluate the feasibility of applying a mechanistic
approach to any particular set of chemicals, one
must assess the validity of the assumptions
against the existing data on endogenous hor-
mones and the chemicals of interest.
The potential for a chemical to exhibit
estrogenic activity at the molecular (or mecha-
nistic) level can be measured by several differ-
ent assays in vitro, including receptor binding
or competitive ligand displacement assays (usu-
ally involving disrupted cells or cell extracts)
and recombinant receptor-reporter gene assays
(cells transfected with an ER-reporter gene
construct), often called transcription activation
assays. Estrogenicity of chemicals has been esti-
mated in vitro using cultures of estrogen
responsive cells (i.e., those already possessing
ERs) such as MCF-7 (the “E-screen” assay) or
T-47-D human breast cancer cells. In these
systems, the end point has been either expres-
sion of specific estrogen-responsive genes or
cell proliferation. In vivo, molecular responses
can be measured as gene expression in estro-
gen-responsive tissues (Andersen et al. 1999;
EDSTAC 1998; Witorsch 2000, 2002;
Zacharewski 1997). The uterotrophic assay
detects estrogenic activity by measuring the
increase in uterine tissue mass in ovari-
ectomized or immature laboratory rodents. It is
considered by many to be the gold standard of
estrogenicity assays because it targets a speciﬁc
response at the physiologic level (Andersen
et al. 1999; EDSTAC 1998; Korach and
McLachlan 1995).
It might seem that determining estrogen
equivalence would be relatively straight-
forward, requiring simply that the potency of
a chemical be measured in one or more of the
available estrogenicity assays and the potency
compared with that of an endogenous estro-
gen such as estradiol-17β. In practice, how-
ever, potency measurements among these
assays can vary widely, making a determina-
tion of estrogen equivalence confusing and
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the same biologic level of hormone action
may produce disparate results. For example,
Chen et al. (1997) showed relatively con-
sistent results for transcription activation by
isomers of DDT and its metabolites dichloro-
diphenyl dichloroethane (DDD) and
dichlorodiphenyl dichloroethylene (DDE)
using two human ER-α (hER-α) reporter
gene constructs. They reported relative poten-
cies for o,p´-DDE of 7.7 × 10–4 to 1 × 10–3
and no activity for p,p´-DDE. In contrast,
Tully et al. (2000) were unable to demon-
strate transcription activation of an hER-α
construct in human carcinoma cells by either
DDT isomer or any of its metabolites.
Balaguer et al. (1999) showed relative poten-
cies for transcriptional activation of hER-α by
DDE isomers in the range of 4 × 10–6 to 7 ×
10–6, while their relative potencies for ER-β
were in the range of 4 × 10–6 to 4 × 10–5.
DDT metabolites and some hydroxylated
PCBs have been shown to stimulate prolifera-
tive responses in estrogen-sensitive cells in
vitro and in vivo (Table 2). Few in vivo stud-
ies using these chemicals have compared the
responses to those produced by an endoge-
nous estrogen, so the data do not allow an
estimate of relative estrogenic potency.
Not only can potency measurements vary
among estrogenicity assays, but hormone
receptor specificity may also be unclear for
some chemicals. Estrogenic and antiestrogenic
effects have been reported for various chlori-
nated hydrocarbons (Safe 1995), some of
which may be found in human milk (LaKind
et al. 2001). A recent, prominent example is
the ability of DDT isomers and metabolites
that show activity in estrogenicity assays to also
interact with the androgen receptor in human
hepatoma cells transfected with a human
androgen receptor-reporter gene construct
(Maness et al. 1998). o,p´-DDE, the most
potent estrogen agonist among the metabolites,
antagonized androgen-stimulated transcription
at concentrations similar to those shown to
have estrogen agonist activity. Not only is it
unclear how to characterize the relative estro-
genic potency of o,p´-DDE (estimates range
2–3 orders of magnitude in various ER tran-
scription activation assays), but it is also
unclear whether this chemical is more potent
as an estrogen or an antiandrogen. Thus, it is
difﬁcult to unambiguously categorize the hor-
monal activity or estimate the hormonal
potency of o,p´-DDE based on the available
data. Some PCB congeners have also recently
been reported to be capable of interacting with
both estrogen and androgen receptors in vitro
at physiologically relevant concentrations
(Bonefeld-Jorgensen et al. 2001). Whether
effects mediated through androgen receptors or
ERs manifest changes in endocrine function in
intact organisms has not been determined.
Thus, for o,p´-DDE and many other chemicals
such as PCBs, estimating estrogenic potency
based on mechanistic information alone does
not seem supportable at this time.
Discrepancies in potency estimates are also
apparent in measurements of transcription acti-
vation by phytoestrogens. Like DDE, some
phytoestrogens show greater afﬁnity for ER-β
than for ER-α; for coumestrol and genistein
these differences are 2-fold and 7-fold, respec-
tively (Whitten and Patisaul 2001). Differential
afﬁnity for ER-α versus ER-β may have func-
tional signiﬁcance because the distribution of
the two receptor isoforms varies among tissues
and during development (Chang and Prins
1999; Gustafsson 2000). Furthermore, ER-α
appears to be the most prevalent ER isoform in
standard binding assays, suggesting that the
estrogenic potency of selected phytoestrogens
might be underestimated. Despite the greater
affinity of genistein for ER-β, recombinant
assay systems (e.g., yeast cells) transfected with
one or the other ER isoform suggest that this
phytoestrogen is more effective in activating
ER-α–transfected cells than ER-β–transfected
cells. In the former, genistein behaves as a full
agonist, whereas in the latter it exhibits partial
agonist activity (Whitten and Patisaul 2001).
In vitro proliferation assays reveal that phy-
toestrogens may either stimulate proliferation
(estrogenic) or inhibit proliferation (antiestro-
genic), a characteristic that is dependent on the
assay system used, their concentration, and
their relative potency. Some phytoestrogens
(e.g., coumestrol and genistein) exhibit biphasic
activity, being proliferative at low concentra-
tions and inhibitory at higher concentrations.
β-Zearalenol has been reported to exhibit
triphasic activity, inhibiting estrogen activity at
low and high concentrations and enhancing
such activity at intermediate concentrations
(Whitten and Patisaul 2001).
Potency estimates relative to estradiol
exhibit marked discrepancies between assay sys-
tems and, in select cases, within assay systems.
For example, ER-binding assays indicate that
coumestrol has a potency relative to estradiol
ranging from 11 to 185%, whereas in transacti-
vational assays and proliferative assays (e.g., E-
screen assays), the relative potency of this
phytoestrogen is much less (less than 0.1%). As
a matter of fact, as shown in Table 2, when
binding assays, in vitro functional assays, and in
vivo end points are compared, discrepancies are
evident for other phytoestrogens (e.g., coume-
strol) and mycoestrogens (α-zearalenone) as well
as for genistein (Whitten and Patisaul 2001).
Whitten and Patisaul (2001) report that
studies have been negative for proliferation of
uterine and vaginal epithelium in rhesus
macaques and rats fed a diet containing the
phytoestrogen genistein. They also report that,
in contrast, other studies have associated nat-
ural dietary exposure to phytoestrogens with
abnormalities in a number of estrogen-
mediated processes in various livestock (e.g.,
cystic ovaries and estrus cycle irregularities).
Phytoestrogen action in laboratory animals
appears to depend on the hormonal milieu,
and so opposite results might be obtained in
pre- versus postpubertal animals. Of eight phy-
toestrogens tested, coumestrol, genistein, and
daidzein appear to be the most potent to stim-
ulate vaginal and uterine growth in vivo in
sheep and mice. Relative to estradiol, the
potency of daidzein and genistein is usually 0.1
to 0.2%, whereas that of coumestrol varies
from less than 0.1% to as much as 20%
(Whitten and Patisaul 2001).
Potency Variation Data and
Implications for Risk
Assessment
In the previous section, we discussed the vari-
ous reasons that a mechanistic risk assessment
approach is currently unsupportable for mix-
tures of estrogenic chemicals. However, it is
important also to discuss the biologic basis of
these reasons so that future research can be
directed toward answering the questions critical
to risk assessment. This section discusses in
some detail the numerous reasons that biologic
potency estimates vary for estrogenic chemicals.
The available assays for estrogenicity
reﬂect a diverse array of molecular elements,
biochemical pathways, and physiologic
processes that mediate the action of endoge-
nous estrogens in different tissues, organs, and
organisms. At the molecular level, there are at
least four distinct estrogenic mechanisms: clas-
sical ligand-dependent, ligand-independent,
DNA binding-dependent, and cell-surface
(nongenomic) signaling (Hall et al. 2001;
Nadal et al. 2001). Assays that test different
molecular mechanisms might be expected to
exhibit dissimilar dose–response characteris-
tics, and none of those could necessarily be
expected to exhibit the same dose–response
relationships as the integrated physiologic
response observed in an intact organism.
Furthermore, because different estrogenic path-
ways can mediate physiologic responses in dif-
ferent tissues and organs, it also seems unlikely
that different physiologic responses would
exhibit the same dose–response characteristics.
Each type of estrogenic assay, be it in vivo or
in vitro, has distinct characteristics that may be
an advantage or a detriment, depending on the
particular objective of the study in question. An
in vivo assay conducted in animals, such as the
uterotrophic assay, assesses the net systemic bio-
logic effects of bioactivation, detoxiﬁcation, and
pharmacokinetic processes as an integral part
of the assay (Andersen et al. 1999; EDSTAC
1998; Zacharewski 1997). Although the
uterotrophic assay may provide an indication of
relatively short-term estrogenic effects (3–5 days’
treatment), it may be unable to detect subtle
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Table 2. Variability in potency estimates for xenoestrogens.
Publication/construct Concentration
or assay chemical (nM/L except as noted) Quantitative response Relative potency
Chen et al. 1997: hER reporter in yeast/Miller units β-galactosidase enzyme activity
Estradiol-17β (reference chemical) 1 0.4360 1.00E + 00
o,p´-DDT 50 0.3960 9.08E – 03
o,p´-DDT 1,000 0.6550 7.51E – 04
o,p´-DDE 1,000 0.6750 7.74E – 04
o,p´-DDD 1,000 0.5810 6.66E – 04
p,p´-DDT 1,000 0.4950 5.68E – 04
p,p´-DDE 1,000 0.0000 0.00E + 00
p,p´-DDA 1,000 0.0000 0.00E + 00
Chen et al. 1997: LexA-hER in CTY10-5d yeast/Miller units β-galactosidase
Estradiol-17β (reference chemical) 1 0.9800 1.00E + 00
o,p´-DDT 1,000 0.1100 1.12E – 04
o,p´-DDE 1,000 0.1010 1.03E – 04
o,p´-DDD 1,000 0.1050 1.07E – 04
p,p´-DDT 1,000 0.0977 9.97E – 05
p,p´-DDE 1,000 0.0000 0.00E + 00
p,p´-DDA 1,000 0.0000 0.00E + 00
Tully et al. 2000: pERET81CAT in HeLa cells/CAT protein immunoassay
Estradiol-17β (reference chemical) 0 0.0000 1.00E + 00
Estradiol-17β (reference chemical) 10 0.2200 1.00E + 00
Estradiol-17β (reference chemical) 100 0.4000 1.00E + 00
Estradiol-17β (reference chemical) 1,000 1.0000 1.00E + 00
p,p´-DDT 1 0.0000 0.00E + 00
p,p´-DDT 10 0.0000 0.00E + 00
p,p´-DDT 100 0.0000 0.00E + 00
p,p´-DDT 1,000 0.0000 0.00E + 00
p,p´-DDT 10,000 0.0000 0.00E + 00
p,p´-DDD 1 0.0000 0.00E + 00
p,p´-DDD 10 0.0000 0.00E + 00
p,p´-DDD 100 0.0000 0.00E + 00
p,p´-DDD 1,000 0.0000 0.00E + 00
p,p´-DDD 10,000 0.0000 0.00E + 00
p,p´-DDE 1 0.0000 0.00E + 00
p,p´-DDE 10 0.0000 0.00E + 00
p,p´-DDE 100 0.0000 0.00E + 00
p,p´-DDE 1,000 0.0000 0.00E + 00
p,p´-DDE 10,000 0.0000 0.00E + 00
p,p´-DDT + p,p´-DDD 2 0.0000 0.00E + 00
p,p´-DDT + p,p´-DDD 20 0.0000 0.00E + 00
p,p´-DDT + p,p´-DDD 200 0.0000 0.00E + 00
p,p´-DDT + p,p´-DDD 2,000 0.0000 0.00E + 00
p,p´-DDT + p,p´-DDD 20,000 0.0000 0.00E + 00
p,p´-DDT + p,p´-DDE 2 0.0000 0.00E + 00
p,p´-DDT + p,p´-DDE 20 0.0000 0.00E + 00
p,p´-DDT + p,p´-DDE 200 0.0000 0.00E + 00
p,p´-DDT + p,p´-DDE 2,000 0.0000 0.00E + 00
p,p´-DDT + p,p´-DDE 20,000 0.0000 0.00E + 00
p,p´-DDD + p,p´-DDE 2 0.0000 0.00E + 00
p,p´-DDD + p,p´-DDE 20 0.0000 0.00E + 00
p,p´-DDD + p,p´-DDE 200 0.0000 0.00E + 00
p,p´-DDD + p,p´-DDE 2,000 0.0000 0.00E + 00
p,p´-DDD + p,p´-DDE 20,000 0.0000 0.00E + 00
Fielden et al. 1997: Speciﬁc binding, mouse uterine cytosol
Estradiol-17β (reference chemical) IC50 1.00E + 00
PCB-104 1,700 IC50 9.09E – 03
OH-PCB-104 700 IC50 2.22E – 01
PCB-155 5,600 IC50 2.76E – 03
Fielden et al. 1997: Gal4-hER in MCF-7 cells/induction of luciferase
Estradiol-17β (reference chemical) 50 69 1.00E + 00
PCB-104 10,000 31.00 2.25E – 03
OH-PCB-104 1,000 15.00 1.09E – 02
OH-PCB-104 10,000 9.00 6.52E – 04
PCB-155 10,000 0.00 0.00E + 00
Balaguer et al. 1999: MELN (hER-α)/luciferase activity per milligram protein
Estradiol-17β (reference chemical) 0.1 1.00 1.00E + 00
o´,p-DDE 10,000 0.72 7.20E – 06
p,p´-DDE 10,000 0.40 4.00E – 06
2,3,7,8-TCDD 1,000 0.30 3.00E – 05
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Table 2. Continued.
Publication/construct Concentration
or assay chemical (nM/L except as noted) Quantitative response Relative potency
Balaguer et al. 1999: HELNα (hER-α)/luciferase activity per milligram protein
Estradiol-17β (reference chemical) 0.1 1.00 1.00E + 00
o,p´-DDE 10,000 0.70 7.00E – 06
p,p´-DDE 10,000 0.42 4.20E – 06
2,3,7,8-TCDD 1,000 –0.10 –1.00E – 05
Balaguer et al. 1999: HELNβ (hER-β)/luciferase activity per milligram protein
Estradiol-17β (reference chemical) 1 1.00 1.00E + 00
o´,p-DDE 10,000 0.40 4.00E – 05
p,p´-DDE 10,000 0.36 3.60E – 05
2,3,7,8-TCDD 1,000 0.00 0.00E + 00
Garner et al. 1999: pERET81CAT in HeLa cells/CAT protein immunoassay
Estradiol-17β (reference chemical) 10 1.00 1.00E + 00
2,5-Dichloro-4´-biphenylol 10,000 0.20 2.03E – 04
2,4,6-Trichloro-4´-biphenyldiol 10,000 0.44 4.42E – 04
3,4-Biphenyldiol 50,000 0.42 8.32E – 05
2,5-Dichloro-3´,4´-biphenyldiol 10,000 0.19 1.86E – 04
2,5-Dichloro-2´,3´-biphenyldiol 10,000 0.06 5.62E – 05
2,4,6-Trichloro-3´,4´-biphenyldiol 10,000 0.36 3.57E – 04
Gierthy et al. 1997: Induction of MCF-7 cells resulting in cellular aggregation or 
multilayered nodules of cells (foci)
Estradiol-17β (reference chemical) 1 1.00 1.00E + 00
2-Chlorobiphenyl 5,000 0.29 5.80E – 05
2-Chloro-4-biphenylol 5,000 0.21 4.20E – 05
4-Chlorobiphenyl 5,000 0.10 2.00E – 05
4-Chloro-4´-biphenylol 5,000 0.35 7.00E – 05
2,5-Dichlorobiphenyl 5,000 0.44 8.80E – 05
2,5-Dichloro-4-biphenylol 5,000 0.76 1.52E – 04
2,5-Dichloro-4-biphenylol 5,000 –0.13 –2.60E – 05
3,5-Dichlorobiphenyl 5,000 0.46 9.20E – 05
3,5-Dichloro-4´-biphenylol 5,000 0.44 8.80E – 05
3,5-Dichloro-4´-biphenylol 5,000 –0.13 –2.60E – 05
2,4,6-Trichlorobiphenyl 5,000 0.48 9.60E – 05
2,4,6-Trichloro-4´-biphenylol 5,000 0.98 1.96E – 04
3,4,5-Trichlorobiphenyl 5,000 0.2000 4.00E – 05
3,4,5-Trichlorobiphenyl 5,000 –0.4000 –8.00E – 05
3,4,5-Trichloro-4-biphenylol 5,000 1.0000 2.00E – 04
Korach et al. 1988: Speciﬁc binding, murine uterine cytosol
Estradiol-17β (reference chemical) N/D N/D 1.00E + 00
4-Hydroxy-2´,3´,4´,5´-tretrachlorobiphenyl N/D N/D 2.38E – 02
4-Hydroxy-2´,4´,6´-trichlorobiphenyl N/D N/D 1.05E – 02
4,4´-Dihydroxy-2´-chlorobiphenyl N/D N/D 1.11E – 02
4-Hydroxy-2´6´-dichlorobiphenyl N/D N/D 2.58E – 03
4-Hydroxy-2´5´-dichlorobiphenyl N/D N/D 1.98E – 03
4-Hydroxy-3,5,4´-trichlorobiphenyl N/D N/D 1.00E – 03
4,4´-Dihydroxy-3,5,3´,5´-tetrachlorobiphenyl N/D N/D 7.39E – 04
4-Hydroxy-2-chlorobiphenyl N/D N/D 4.00E – 04
4-Hydroxy-4´-chlorobiphenyl N/D N/D 2.56E – 04
4,4´-Dihydroxy-2´,3´,5´,6´-tetrachlorobiphenyl N/D N/D 2.00E – 04
4,4´-Dihydroxybiphenyl N/D N/D < 2.00E – 04
4-Hydroxybiphenyl N/D N/D < 2.00E – 04
Bonefeld-Jorgensen et al. 2001: pERE-tk-CAT in MCF-7 cells/CAT protein immunoassay
Estradiol-17β (reference chemical) 10 1.000000 1.00E + 00
PCB-138 9,000 –0.610000 –6.78E – 04
PCB-153 9,000 –0.500000 –5.56E – 04
PCB-180 9,000 –0.790000 –8.78E – 04
PCB-138 + E2 9,000 + 10 –0.360000 –4.00E – 04
PCB-153 + E2 9,000 + 10 –0.410000 –4.56E – 04
PCB-180 + E2 9,000 + 10 –0.750000 –8.33E – 04
PCB-138 + PCB-153 + PCB-180 3,000 + 3,000 + 3,000 –0.420000 –4.67E – 04
PCB-138 + PCB-153 + PCB-180 = E2 3,000 + 3,000 + 3,000 + 10 –0.270000 –3.00E – 04
Smeets et al. 1999: Vitellogenin induction in Carp hepatocyte cells
Estradiol-17β (reference chemical) 2 LOEC 1.00E + 00
DES 6 LOEC 5.00E – 01
Methoxychlor 5,000 LOEC 1.00E – 03
o,p-DDT 25,000 LOEC 2.00E – 04
Chlordecone 20,000 LOEC 1.00E – 04
Bisphenol A 50,000 LOEC 1.00E – 04
4-t-Pentylphenol 50,000 LOEC 1.00E – 04
o,p-DDE ND LOEC ND
Toxaphene ND LOEC ND
β-Endosulfan ND LOEC ND
Dieldrin ND LOEC ND
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Table 2. Continued.
Publication/construct Concentration
or assay chemical (nM/L except as noted) Quantitative response Relative potency
Metcalfe et al. 2001: Yeast estrogen screen assay—effective concentration 
inducing 20% of maximum response observed with E2
Estradiol-17β (reference chemical) 0.022000 EC20 (ng/mL) 1.00E + 00
Ethinylestradiol-17α 0.059 EC20 (ng/mL) 3.80E – 01
Estrone 0.166 EC20 (ng/mL) 1.40E – 01
Estriol 0.627 EC20 (ng/mL) 3.70E – 02
Nonylphenol 246.7 EC20 (ng/mL) 8.90E – 05
Nonylphenol monoethoxylate 10,985.4 EC20 (ng/mL) 2.00E – 06
Nonylphenol monoethoxylate/nonylphenol diethoxylate 9,627.6 EC20 (ng/mL) 2.30E – 06
Nonylphenol monoethoxycarboxylate 0.0 EC20 (ng/mL) 0.00E + 00
Nonylphenol monoethoxycarboxylate/nonylphenol diethoxycarboxylate 0.0 EC20 (ng/mL) 0.00E + 00
Bisphenol A 597.3 EC20 (ng/mL) 3.70E – 05
Diethylhexyl phthalate 0.0 EC20 (ng/mL) 0.00E + 00
Madigou et al. 2001: Rainbow trout hepatocyte culture/induction of vitellogenin mRNA
Estradiol-17β (reference chemical) 1,000 100 1.00E + 00
4-n-Nonylphenol 10,000 22 2.20E – 02
4-n-Nonylphenol diethoxylate 10,000 0 0.00E + 00
4-n-Nonylphenol diethoxylate 100,000 0 0.00E + 00
Nonylphenol glucuronide 1,000 0 0.00E + 00
Nonylphenol glucuronide 10,000 0 0.00E + 00
3-(4-Hydroxyphenol)-propionic acid 10,000 0 0.00E + 00
3-(4-Hydroxyphenol)-propionic acid 100,000 0 0.00E + 00
4-Hydroxybenzoic acid 10,000 0 0.00E + 00
4-Hydroxybenzoic acid 100,000 0 0.00E + 00
Madigou et al. 2001: 2ERE-CYC1-lacZ in yeast/Miller units β-galactosidase
Estradiol-17β (reference chemical) 100 100 1.00E + 00
4-n-Nonylphenol 10,000 92 9.20E – 03
4-n-Nonylphenol diethoxylate 100,000 0 0.00E + 00
Nonylphenol glucuronide 100,000 0 0.00E + 00
3-(4-Hydroxyphenol)-propionic acid 100,000 0 0.00E + 00
4-Hydroxybenzoic acid 100,000 0 0.00E + 00
Andersen et al. 1999: Recombinant hER in MCF-7 cells/direct competitive binding
Estradiol-17β (reference chemical) 1 IC50 1.00E + 00
Ethynyl estradiol-17α (standard) 0.67 IC50 2.20E + 00
DES 0.25 IC50 5.80E + 00
Tamoxifen 2.6 IC50 6.00E – 01
ICI 182.780 3.6 IC50 4.00E – 01
Testosterone > 200,000 IC50
Bisphenol A 11,000 IC50 1.30E – 04
Bisphenol A dimethacrylate > 0.00000002 IC50
4-n-OP 4,000 IC50 3.60E – 04
4-n-NP 4,300 IC50 3.40E – 04
NP12EO 57,000 IC50 2.50E – 05
BBP 12,000 IC50 1.20E – 04
DBP > 200,000 IC50
Methoxychlor > 200,000 IC50
o,p-DDT 5I C 50 2.90E – 03
p, p´-DDE 16,000 IC50 9.10E – 05
Endosulfan 13,000 IC50 1.20E – 04
Chlormequat chloride 56,000 IC50 2.60E – 05
Colchicine > 200,000 IC50
Andersen et al. 1999: Rabbit uterine tissue/In vitro ER binding assay
Estradiol-17β (reference chemical) 0.02 IC50 1.00E + 00
Ethynyl estradiol-17α (standard) 0.002 IC50 1.00E + 01
DES 0.000007 IC50 2.86E + 03
Tamoxifen 120 IC50 1.70E – 04
ICI 182.780 0.004 IC50 5.00E + 00
Testosterone > 10,000 IC50
Bisphenol A 1,600 IC50 1.30E – 05
Bisphenol A dimethacrylate 4,300 IC50 4.70E – 06
4-n-OP > 10,000 IC50
4-n-NP 1,800 IC50 1.10E – 05
NP12EO > 10,000 IC50
BBP > 10,000 IC50
DBP > 10,000 IC50
Methoxychlor 6,500 IC50 3.10E – 06
o,p-DDT 3,400 IC50 5.90E – 06
p, p´-DDE > 10,000 IC50
Endosulfan > 10,000 IC50
Chlormequat chloride > 10,000 IC50
Colchicine > 10,000 IC50
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Publication/construct Concentration
or assay chemical (nM/L except as noted) Quantitative response Relative potency
Le Guevel and Pakdel 2001: Recombinant yeast expressing hER/β-galactosidase induction
Ethynyl estradiol-17α (reference chemical) 1 EC50 1.00E + 00
DES 2.9 EC50 2.10E – 01
Estradiol-17β 0.74 EC50 8.30E – 01
Estradiol-17α 5.2 EC50 1.20E – 01
Estrone 2.1 EC50 2.90E – 01
Zearalenone 130 EC50 5.00E – 03
Zeralanone 110 EC50 6.00E – 03
α-Zearalenol 30 EC50 2.20E – 02
β-Zearalenol 280 EC50 0.00E + 00
α-Zearalanol 4,000 EC50 1.40E – 02
β-Zearalanol 160 EC50 4.00E – 03
Le Guevel and Pakdel 2001: Rainbow trout ER in recombinant yeast/β-galactosidase units
Ethynyl estradiol-17α (reference chemical) 3.6 EC50 1.00E + 00
DES 4.3 EC50 8.20E – 01
Estradiol-17β 5.2 EC50 6.80E – 01
Estradiol-17α 140 EC50 3.00E – 02
Estrone 22 EC50 1.60E – 01
Zearalenone 62 EC50 6.00E – 02
Zeralanone 32 EC50 1.10E – 01
α-Zearalenol 12 EC50 2.90E – 01
β-Zearalenol > 50,000 EC50 > 1.00E – 04
α-Zearalanol 30 EC50 1.10E – 01
β-Zearalanol 110 EC50 3.00E – 02
Behnisch et al. 2001: E-screen assay with calf MCF-7 cells
Estradiol-17β (standard) 0.0062 EC50 1.00E + 00
Ethynyl estradiol-17α (reference chemical) 0.0021 EC50 3.00E + 00
Bisphenol A 110 EC50 5.60E – 04
Butyl benzylpthalate 490 EC50 1.30E – 05
Di-n-butylphthalate 1,700 EC50 3.60E – 06
4-Octylphenol 320 EC50 1.90E – 05
Nikov et al. 2000: Phytoestrogen binding to hER-α
Estradiol-17β (reference chemical) 13 ± 0.7 IC50 1.00E + 00
Genistein 825 ± 2 IC50 1.60E – 02
Coumestrol 109 ± 1 IC50 1.20E – 01
Zearalenone 59 ± 0.8 IC50 2.20E – 01
Daidzein 7 ± 1 IC50 2.00E – 03
Glyceolin 6 ± 0.6 IC50 2.20E – 03
Testosterone 35 ± 0.5 IC50 4.00E – 04
Nikov et al. 2000: Phytoestrogen binding to hER-β
Estradiol-17β (reference chemical) 12 ± 0.5 IC50 1.00E + 00
Genistein 12 ± 0.7 IC50 1.00E + 00
Coumestrol 35 ± 0.7 IC50 3.40E – 01
Zearalenone 16 ± 0.5 IC50 7.50E – 01
Daidzein 670 ± 1 IC50 1.80E – 02
Glyceolin 16 ± 1.4 IC50 8.00E – 04
Testosterone 20 ± 1 IC50 6.00E – 04
Harper et al. 1994: Progesterone receptor induction in MCF-7 human breast cancer cells
Estradiol-17β (reference chemical) 1 283 1.00E + 00
TCDD 18 4 2.97E – 01
Eroschenko et al. 2000: Reproductive tract weight in ovariectomized adult mice;
note concentrations in nanograms.
Estradiol-17β (reference chemical) 25 1.6 1.00E + 00
Methoxychlor 125,000,000 1.1 1.38E – 07
Danzo 1997: Percent binding to rabbit uterine cytosol ERs using the charcoal assay procedure
Estradiol-17β (reference chemical) 1.00E + 00
5α-Dihydrotestosterone 8.50E – 01
Hexachlorocyclohexane 1.15E + 00
Hexachlorocyclohexane 1.19E + 00
Methoxychlor 8.80E – 01
p, p´-DDE 9.00E – 01
DDE 9.20E – 01
o,p-DDT 4.00E – 01
Dieldrin 9.70E – 01
Atrazine 9.80E – 01
Pentachlorophenol 8.20E – 01
Nonylphenol 2.50E – 01
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Publication/construct Concentration
or assay chemical (nM/L except as noted) Quantitative response Relative potency
Matthews et al. 2000: Binding to human α-GST ERs
Estradiol-17β (reference chemical) 0.29 IC50 1.00E + 00
4-Hydroxytamoxifen 1.90 IC50 1.55E + 00
Ethynyl estradiol 2.30 IC50 1.27E + 00
DES 3.20 IC50 9.10E – 01
α-Zearalanol 6.10 IC50 4.80E – 01
Estrone 6.50 IC50 4.50E – 01
ICI 164, 384 7.00 IC50 4.20E – 01
Estriol 10.00 IC50 2.80E – 01
β-Zearalanol 23.00 IC50 1.30E – 01
Tamoxifen 28.00 IC50 1.10E – 01
Estradiol benzoate –9.00 IC50 1.00E – 01
Zearalenone 31.00 IC50 9.30E – 02
HPTE 250.00 IC50 1.20E – 02
Coumestrol 360.00 IC50 8.10E – 03
Genistein 630.00 IC50 4.60E – 03
4-t-Octylphenol 2,400.00 IC50 1.20E – 03
Dihydrotesterone 5,900.00 IC50 4.90E – 04
Bisphenol A 36,000.00 IC50 8.00E – 05
Kepone 42,000.00 IC50 6.90E – 05
Matthews et al. 2000: Binding to mouse α-GST ERs
Estradiol-17β (reference chemical) 2.70 IC50 1.00E + 00
4-Hydroxytamoxifen 1.20 IC50 2.12E + 00
Ethynyl estradiol 2.20 IC50 1.18E + 00
DES 3.20 IC50 8.40E – 01
α-Zearalanol 5.10 IC50 5.30E – 01
Estrone 9.50 IC50 2.80E – 01
ICI 164, 384 5.90 IC50 4.50E – 01
Estriol 21.00 IC50 1.30E – 01
β-Zearalanol 24.00 IC50 1.10E – 01
Tamoxifen 26.00 IC50 1.00E – 01
Estradiol benzoate 23.00 IC50 1.20E – 01
Zearalenone 23.00 IC50 1.20E – 01
HPTE 220.00 IC50 1.20E – 02
Coumestrol 800.00 IC50 3.30E – 03
Genistein 810.00 IC50 3.30E – 03
4-t-Octylphenol 1,600.00 IC50 1.70E – 03
Dihydrotesterone 6,600.00 IC50 4.00E – 04
Bisphenol A 31,000.00 IC50 8.60E – 05
Kepone 64,000.00 IC50 3.50E – 05
o,p-DDT 36,000.00 IC50 7.30E – 05
Matthews et al. 2000: Binding to chicken α-GST ERs
Estradiol-17β (reference chemical) 3.20 IC50 1.00E + 00
4-Hydroxytamoxifen 1.90 IC50 1.68E + 00
Ethynyl estradiol 1.90 IC50 1.71E + 00
DES 2.50 IC50 1.30E + 00
α-Zearalanol 4.60 IC50 7.00E – 01
Estrone 6.40 IC50 5.00E – 01
ICI 164, 384 5.20 IC50 6.20E – 01
Estriol 29.00 IC50 1.10E – 01
β-Zearalanol 14.00 IC50 2.30E – 01
Tamoxifen 21.00 IC50 1.60E – 01
Estradiol benzoate 22.00 IC50 1.50E – 01
Zearalenone 9.90 IC50 3.30E – 01
HPTE 68.00 IC50 4.80E – 02
Coumestrol 460.00 IC50 7.00E – 03
Genistein 410.00 IC50 7.80E – 03
4-t-Octylphenol 560.00 IC50 5.70E – 03
Dihydrotesterone 38,000.00 IC50 8.50E – 05
Bisphenol A 7,300.00 IC50 4.40E – 04
Kepone 30,000.00 IC50 1.10E – 03
o,p-DDT 37,000.00 IC50 8.60E – 04
Quercitin 82,000.00 IC50 3.90E – 05
Naringenin 39,000.00 IC50 8.20E – 05
Matthews et al. 2000: Binding to green anole α-GST ERs
Estradiol-17β (reference chemical) 3.10 IC50 1.00E + 00
4-Hydroxytamoxifen 1.30 IC50 2.43E + 00
Ethynyl estradiol 2.20 IC50 1.39E + 00
Diethylstilbestrol 2.90 IC50 1.07E + 00
α-Zearalanol 8.60 IC50 3.60E – 01
Estrone 5.10 IC50 6.00E – 01
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ICI 164, 384 11.00 IC50 2.80E – 01
Estriol 10.00 IC50 3.00E – 01
β-Zearalanol 73.00 IC50 4.20E – 02
Tamoxifen 30.00 IC50 1.00E – 01
Estradiol benzoate 24.00 IC50 1.30E – 01
Zearalenone 27.00 IC50 1.20E – 01
HPTE 64.00 IC50 4.80E – 02
Coumestrol 100.00 IC50 3.10E – 02
Genistein 240.00 IC50 1.30E – 02
4-t-Octylphenol 3,900.00 IC50 7.90E – 04
Dihydrotesterone 820.00 IC50 3.80E – 03
Bisphenol A 2,400.00 IC50 1.30E – 03
Kepone 27,000.00 IC50 1.10E – 04
Quercitin 19,000.00 IC50 1.60E – 04
Naringenin 4,700.00 IC50 6.50E – 04
Matthews et al. 2000: Binding to rainbow trout α-GST ERs
Estradiol-17β (reference chemical) 3.30 IC50 1.00E + 00
4-Hydroxytamoxifen 1.20 IC50 2.72E + 00
Ethynyl estradiol 3.10 IC50 1.08E + 00
DES 2.00 IC50 1.65E + 00
α-Zearalanol 1.30 IC50 2.67E + 00
Estrone 24.00 IC50 1.40E – 01
ICI 164, 384 1.00 IC50 3.27E + 00
Estriol 90.00 IC50 3.70E – 02
β-Zearalanol 3.70 IC50 9.10E – 01
Tamoxifen 13.00 IC50 2.50E – 01
Estradiol benzoate 3.70 IC50 9.00E – 02
Zearalenone 4.10 IC50 8.20E – 01
HPTE 24.00 IC50 1.40E – 01
Coumestrol 1,400.00 IC50 2.40E – 03
Genistein 750.00 IC50 4.40E – 03
4-t-Octylphenol 1.10 IC50 3.20E – 02
Dihydrotesterone 10,000.00 IC50 3.40E – 04
Bisphenol A 1,600.00 IC50 2.10E – 03
Kepone 6,200.00 IC50 5.40E – 04
Naringenin 8,700.00 IC50 3.90E – 04
DHEA 12,000.00 IC50 2.80E – 04
Quercitin 8,000.00 IC50 4.20E – 04
o,p´-DDT 780.00 IC50 4.30E – 03
o,p´-DDE 3,200.00 IC50 1.10E – 03
p,p´-DDE 8,000.00 IC50 4.20E – 04
Dibutylbenzylphthalate 1,700.00 IC50 2.00E – 03
α-Endosulfan 28,000.00 IC50 1.20E – 04
Methoxychlor 3,500.00 IC50 9.50E – 03
Diel et al. 2000: Uterotrophic assay in ovariectomized 14-day-old DA/Han rats
Ethynyl estradiol-17α (reference chemical) 0.10 1,300 1.00E + 00
o,p´-DDT 10 42 3.23E – 04
o,p´-DDT 100 446 3.43E – 04
o,p´-DDT 500 665 1.02E – 04
Lemini et al. 1997: Uterotrophic activity in immature CD1 mice measured as 
uterine weight (mg)
Estradiol-17β (reference chemical) 1 µg/100 g 64 ± 4.4 1.00E + 00
p-Hydroxybenzoic acid (PHBA) 500 µg/100 g 63 ± 4.5 1.10E – 03
Lemini et al. 1997: Uterotrophic activity in ovariectomized CD1 mice measured as 
uterine weight (mg)
Estradiol-17β (reference chemical) 1 µg/100 g 137 ± 11 1.00E + 00
p-Hydroxybenzoic acid (PHBA) 500 µg/100 g 92 ± 6.5 1.80E – 03
Katsuda et al. 2000: Uterotrophic assay in adult Crj:Donryu rats measured as 
uterine weight (g)—2-day treatment
Estradiol-17β (reference chemical) 0.005 0.618 1.00E + 00
p-tert-Octylphenol 6.25 0.150 1.94E – 04
p-tert-Octylphenol 12.5 0.147 9.51E – 05
p-tert-Octylphenol 25 0.175 5.66E – 05
p-tert-Octylphenol 50 0.202 3.27E – 05
p-tert-Octylphenol 100 0.285 2.31E – 05
p-tert-Octylphenol 200 0.381 1.54E – 05
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Table 2. Continued.
Publication/construct Concentration
or assay chemical (nM/L except as noted) Quantitative response Relative potency
Katsuda et al. 2000: Uterotrophic assay in adult Crj:Donryu rats measured as 
uterine weight (g)—14 day treatment
Estradiol-17β (reference chemical) 0.005 0.148 1.00E + 00
p-tert-Octylphenol 6.25 0.132 7.14E – 04
p-tert-Octylphenol 12.5 0.142 3.84E – 04
p-tert-Octylphenol 25 0.233 3.15E – 04
p-tert-Octylphenol 50 0.305 2.06E – 04
p-tert-Octylphenol 100 0.422 1.43E – 04
Santell et al. 1997: Uterotrophic assay in immature or adult ovariectomized 
Sprague-Dawley rats measured as uterine weight (mg)
Estradiol-17β (reference chemical) 0.5 µg/kg 122.1 1.00E + 00
Estradiol-17β (standard) 1.0 µg/day 194.8 7.98E – 01
Estradiol-17β (standard) 1.5 µg/day 255 6.96E – 01
Genistein 150 µg/day 92.4 2.52E – 03
Genistein 375 µg/day 135.6 1.48E – 03
Genistein 750 µg/day 189.3 1.03E – 03
Petroff et al. 2000: Uterotrophic assay in immature Sprague-Dawley rats 
measured as uterine weight (mg)
Estradiol cypionate (reference chemical) 2 41.9 1.00E + 00
TCDD 0.010 38.1 1.82E + 02
Cummings and Laws 2000: Percent implanting in female Holtzman rats
Estrone (reference chemical) 0.001 mg/kg 100 1.00E + 00
Methoxychlor 6.25 mg/kg 10 1.60E – 05
Methoxychlor 12.5 mg/kg 8 6.40E – 06
Methoxychlor 25 mg/kg 37 1.48E – 05
Methoxychlor 50 mg/kg 68 1.36E – 04
Methoxychlor 100 mg/kg 57 5.70E – 06
Methoxychlor 200 mg/kg 70 3.50E – 06
Methoxychlor 300 mg/kg 100 3.33E – 06
Bisphenol A 25 mg/kg 30 1.20E – 05
Bisphenol A 50 mg/kg 50 1.00E – 05
Bisphenol A 100 mg/kg 78 7.80E – 06
Bisphenol A 200 mg/kg 100 5.00E – 06
4-tert-Octylphenol 200 mg/kg 25 1.25E – 06
4-tert-Octylphenol 300 mg/kg 22 7.33E – 07
4-tert-Octylphenol 400 mg/kg 75 1.88E – 06
Jansen et al. 1993: Uterotrophic assay in immature Sprague-Dawley rats measured as 
uterine weight (mg)
Estradiol-17β (reference chemical) 1 µg/day 60 1.00E + 00
PCB-77 160 µg/day 25 2.60E – 03
PCB-52 640 µg/day 32 8.33E – 04
OH-PCB 250 µg/day 28 1.87E – 03
Aroclor 1242 80 µg/day 31 6.46E – 03
Aroclor 1242 320 µg/day 34 1.77E – 03
Fielden et al. 1997: Uterotrophic activity in ovariectomized CD1 mice measured as 
uterine weight (g)
Ethynyl estradiol-17α (reference chemical) 0.10 1.1 2.39E + 00
Ethynyl estradiol-17α (reference chemical) 1.0 4.6 1.00E + 00
PCB-104 1.7 1.1 5.88E – 02
PCB-104 16 1.3 7.39E – 03
PCB-104 202 1.8 8.10E – 04
Carlson and Williams 2001: Plasma vitellogenin induction in rainbow trout
Estradiol-17β (reference chemical) 1.00E + 00
Estrone 1.00E + 00
OH-PCB-30 1.00E – 01
OH-PCB-61 1.00E – 03
PCB-30 0.00E + 00
PCB-61 0.00E + 00
PCB-75 0.00E + 00
PCB-114 0.00E + 00
Abbreviations: CAT, choline acetyltransferase; GST, glutathione S-transferase; h, human; LOEC, lowest observable effect concentration; ND, no data; VTG, vitellogenin; YES, yeast estro-
gen screen. Data from tables or visually extracted from graphs in selected publications were used to calculate relative estrogenic potencies according to the following formula: [RT/CT ×
CSTD]/RSTD, where R denotes the measured response, and C denotes the concentration of either the estrogenic standard (STD) or test chemical (T). Negative values indicate anti-estro-
genic potencies, i.e., the ability of a chemical to antagonize the response to the estrogenic standard. For the mixtures studied by Boneﬁeld-Jorgensen et al. (2001), the mathematical sum
of the component concentrations was assumed for CT, including the estrogenic standard, i.e., 9,000 nM PCB + 10 nM E2 was assumed to be 9,010 nM.estrogenic effects that may occur after long-
term, low-level exposures. A positive response in
the uterotrophic assay requires higher levels of
estradiol than in vitro receptor binding and
transactivational assays (Zacharewski 1997), an
aspect that has caused some to speculate that the
uterotrophic assay may be unable to detect
weakly estrogenic substances. Given this specu-
lation, some have argued that potency estimates
should be based on more sensitive in vitro assays
to ensure that the potency of weak estrogens is
incorporated into potency estimates for mixtures
of estrogenic compounds (EDSTAC 1998;
Payne et al. 2001). However, it seems that
potency estimates obtained via animal assays
would actually be a more appropriate prediction
of what might occur under real-life circum-
stances than in vitro assays. In whole-animal
assays, pharmacokinetic processes can inﬂuence
the pharmacodynamic responses of integrated
physiologic systems.
In vitro assays, on the other hand, are un-
able to fully assess a number of processes that
determine the in vivo activity of endogenous
hormones and exogenous chemicals, includ-
ing metabolism, pharmacokinetics, and inter-
action with other hormones and hormonal
systems (Andersen et al. 1999; Degen and
Bolt 2000; Zacharewski 1997). Therefore,
potency comparisons based on in vitro or
short-term in vivo assays may not predict
long-term effects in intact organisms. For this
reason, such assays are typically regarded as
useful screens (Andersen et al. 1999; Degen
and Bolt 2000; EDSTAC 1998; Shelby et al.
1996) and it would seem that potency data
derived from such studies could not be used
in comparative risk assessments without
detailed knowledge of the physiologic, bio-
chemical, and pharmacokinetic properties of
the chemical in the target organism.
The potential for systemic metabolic trans-
formation to alter the activity of substances
in vivo is of particular concern for estrogenic
screening assays. Specifically, there has been
concern that receptor binding, cell prolifera-
tion, and yeast-based transcription assays might
produce false-negative or false-positive results
for the prediction of estrogenic activity in vivo
because of the absence of metabolic transfor-
mation of the chemicals in question by periph-
eral tissues. Such metabolic transformation
may not only inactivate chemicals with hor-
monal activity, but can also metabolize a num-
ber of chemicals to active metabolites (Charles
et al. 2000; Connor et al. 1997; Elsby et al.
2000, 2001a, 2001b; Fertuck et al. 2001;
Garner et al. 1999; Nakagawa and Suzuki
2002; Sugihara et al. 2000). Active metabolites
may have mechanisms of action and potencies
different from the parent compound. In vitro
assays that differ in metabolic capability can
produce different relative potency measure-
ments, depending on the chemical (Le Guevel
and Pakdel 2001). For example, a cell prolifer-
ation assay in Ishikawa cells and transcription
activation assays in yeast assays produced EC50
concentrations (concentrations that elicted
50% of the maximum effect) for estradiol-17β
that were within an order of magnitude,
depending on whether the recombinant yeast
assay utilized hER or rainbow trout ER. In
those same assays, however, EC50 concentra-
tions differed by 3–4 orders of magnitude for
the mycotoxin zearalenone, for individual
metabolites of zearalenone, for various syn-
thetic estrogens, and for diethylstilbestrol
(DES). Although the absolute potency differ-
ences between chemicals were not identical in
the yeast assay, incorporating recombinant ERs
yields a much greater potency difference
between estradiol-17β and some of the syn-
thetic estrogens than was observed in the
Ishikawa cell proliferation assay (Le Guevel
and Pakdel 2001).
Pharmacokinetic differences can also be
sufficient to alter relative estrogenic potency
at the physiologic level relative to the molecu-
lar level. Daidzein is a prime example of how
inefficient gastrointestinal absorption and
rapid urinary elimination alter estrogenic
potency in rats (Bayer et al. 2001) relative to
ER affinity or functional potency in vitro
(Hopert et al. 1998).
In addition to differences in absorption
and elimination kinetics, differential binding
to serum proteins can create large differences
in the cellular uptake and cellular response to
different estrogens. Endogenous sex steroid
hormones are bound extensively to plasma
proteins, the most signiﬁcant of which appears
to be sex hormone binding globulin (SHBG).
SHBG is a plasma glycoprotein that binds a
number of circulating steroid hormones with
high afﬁnity, including testosterone, dihydro-
testosterone, and estradiol. Because sex hor-
mones bound to SHBG are restricted from
crossing cell membranes to activate hormone
receptors in target cells, SHBG is generally
thought to regulate hormone action passively
by controlling free plasma concentrations
(reviewed in Westphal 1986). Because SHBG
controls the delivery of the endogenous hor-
mone to a target cell, it was suggested that the
in vivo potency of endogenous hormones
would be less than predicted by in vitro assays
because of their sequestration by SHBG in
plasma. Nagel et al. (1997) hypothesized that
if xenoestrogens have a lower affinity for
SHBG and access of estrogenic chemicals to
the cell were less restricted, the potency of
weak estrogens in vivo might be underesti-
mated in standard in vitro assays. A number of
phytoestrogens and industrial chemicals have
been shown to bind SHBG with afﬁnities far
less than those of endogenous steroids
(Hodgert Jury et al. 2000). Hodgert Jury et al.
(2000) suggest that low-afﬁnity binding may
be physiologically signiﬁcant when SHBG lev-
els are low, as occurs in prepubertal children,
or are artiﬁcially reduced, as occurs with oral
contraceptive use.
Nagel et al. (1998) examined the effect of
plasma binding of a limited number of xeno-
estrogens by comparing their uptake by MCF-7
human breast cancer cells in the presence and
absence of 100% adult male human serum.
These studies revealed that plasma binding (and
hence uptake) of such chemicals is highly vari-
able and does not appear to be predictable by
the chemical nature or type of substance in-
volved. For example, the effective free fraction
(or fraction unrestricted by plasma protein) var-
ied by as much as 30-fold among the phytoe-
strogens and more than 60-fold among the
synthetic estrogens. The effective free fraction
of the SERM (selective ER modulator) ralox-
ifene was 10-fold that of another SERM,
tamoxifen. The effective free fraction of the
alkylphenol nonylphenol was estimated to be
4-fold that of octylphenol. The influence of
plasma binding also varied greatly among
classes of xenoestrogens (Nagel et al. 1998).
Similarly, a signiﬁcant variation in the degree of
SHBG binding of xenoestrogens is suggested by
the ﬁndings of Hodgert Jury et al. (2000) using
a different methodology (ammonium sulfate
precipitation method).
Although the ER is quite promiscuous,
having the ability to bind a chemically diverse
array of substances (Blair et al. 2000), binding
per se does not explain the qualitative nature of
a biologic response resulting from such a lig-
and-ER interaction. Such a response could be
estrogenic (or agonistic), mimicking the action
of estrogen, or can be antiestrogenic (or antag-
onistic). The quality (or direction) of such a
response appears to be a function of the partic-
ular ligand and target tissue involved. This
dependence on substance and target tissue is
exemplified dramatically by a comparison of
the response proﬁle of estradiol with those of
two therapeutic agents, tamoxifen and ralox-
ifene, on four speciﬁc end points: cell prolifera-
tion in the breast, cell proliferation in the
uterus, blood levels of LDL cholesterol, and
bone density (or prevention of osteoporosis).
Estradiol stimulates breast and uterine cell pro-
liferation, lowers blood LDL cholesterol, and
maintains bone density. Tamoxifen is anti-
estrogenic in breast, but mimics the action of
estradiol in uterus, blood LDL cholesterol, and
bone. Raloxifene, on the other hand, is anti-
estrogenic in the uterus as well as the breast
and mimics estradiol action on blood LDL
cholesterol and bone. The distinct response
profiles and their clinical significance are
reviewed elsewhere (Witorsch 2000, 2002).
The mechanisms governing the nature of
the biologic response to an ER ligand appear to
be multifactorial. Aspects of these mechanisms
involve: a) the particular ER isoform (α or β)
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activated, b) ligand-induced conformation
changes in the receptor, c) co-regulatory proteins
that associate with the ligand-receptor complex,
and d) the association between the ligand-ER
complex and other transcription factors and
genomic sites within the cell (Witorsch 2000,
2002). Chirality is another factor that inﬂuences
the potency and/or nature of the biologic
response to an ER ligand. Unlike symmetrical
compounds, mirror images of asymmetric (or
chiral) chemicals, referred to as enantiomers, dif-
fer from one another with regard to the orienta-
tion of their elements in space. Chirality also
potentially impacts estrogenic activity; certain
enantiomers have been shown to exhibit marked
differences in ER binding and biologic activity
(Witorsch 2000, 2002).
Antiestrogenic effects may also occur by
mechanisms other than those described above.
2,3,7,8-Tetrachlorodibenzo-p-dioxin
(TCDD) and certain PCBs that share chemi-
cal characteristics with this compound exhibit
little binding to the ER but are ligands for
another transcription factor, the Ah receptor
(AhR). Antiestrogenicity exhibited by these
dioxin-like compounds involves cross-talk
between the AhR signaling pathway and that
of the ER. A complex resulting from activa-
tion of the AhR evokes an antiestrogenic effect
by interfering with the ability of ER-ligand
complex to interact with the latter’s genomic
site (Safe 1998).
In summary, there are numerous reasons
for inter- and intraassay variation in estimating
the estrogenic potency of environmental chem-
icals. These include a) the existence of several
distinct molecular mechanisms of estrogen
action, b) factors that distinguish in vivo from
in vitro conditions (e.g., metabolic transforma-
tion of the ligand, pharmacokinetic and phar-
macodynamic factors, and SHBG binding),
c) the multitude of factors that confer tissue
speciﬁcity of the direction of a ligand-induced
response (estrogenic or antiestrogenic), d) chi-
rality of ligands, and e) cross-talk between sig-
naling pathways. Because these factors are
complex and not completely understood, it is
difficult at this stage to choose appropriate
assay conditions to standardize the potency of
these substances for use in risk estimation.
Methods for Assessing
Estrogenic Potency of Mixtures
Because sources of infant nutrition may contain
a variety of estrogenic substances, assessing
estrogenicity of infant formulas and endoge-
nous and exogenous chemicals in human milk
requires methods to address mixtures rather
than single chemicals. Mixture assessments
follow one of two basic approaches: Either the
mixture is treated as a single substance, using
dose–response data for the mixture as a whole
(the so-called whole- mixture approach), or
dose–response characteristics of the mixture are
predicted from data on the mixture components
(the so-called component-based approach).
Assessing the whole mixture. Whole-mixture
approaches obviate the need to assess interac-
tions among individual mixture components
and are therefore the most direct way to com-
pare different mixtures (Feron et al. 1998; U.S.
EPA 1986, 1988, 2000). The EDSTAC recom-
mendations to screen speciﬁc mixtures of chem-
icals for endocrine activity (EDSTAC 1998)
implied a whole-mixture approach.
The chief disadvantage of whole-mixture
approaches is that a large number of different
mixtures would need to be tested individ-
ually, because even small differences in mix-
ture composition can affect toxicologic and
dose–response characteristics, making it difﬁ-
cult to extrapolate data from one mixture to
other mixtures. Without a way to extrapolate
data from one mixture to a similar mixture,
different infant nutrition sources would have
to be treated as distinct, separate mixtures and
estrogenic dose–response data generated and
compared for each. Generating dose–response
data for a whole mixture presents additional
difﬁculties, because concentrating or diluting a
mixture to produce a range of concentrations
changes the dose-equivalent ratios of mixture
components. Because mixture effects vary with
both concentrations and ratios of the con-
stituents (Berenbaum 1989; Borgert et al.
2001; Greco et al. 1995), an elaborate toxico-
logic assessment of individual whole mixtures
is usually not practically or technically feasible.
Because of concerns about designing and
interpreting mixtures studies, a joint commit-
tee of the Science Advisory Board and Science
Advisory Panel (SAB/SAP) of the U.S. EPA
recommended that screening and testing of
mixtures for hormonal potential be delayed
until the feasibility of such an approach could
be assessed with the benefit of data on indi-
vidual chemicals (SAB 1999). The technical
limitations inherent in performing whole-
mixture studies may also explain the paucity
of toxicology data on the mixtures of exoge-
nous chemicals that may be found in human
milk or in other sources of infant nutrition.
Despite those challenges, a few published
mixture studies have potential relevance to
sources of infant nutrition. A reconstituted
mixture of PCB congeners similar to the pro-
file of PCB congeners detected in human
milk samples was more potent as an estrogen
and as an antiandrogen in rats than Aroclor
1254, which is a technical-grade mixture of
PCB congeners (Hany et al. 1999). The
reconstituted mixture was effective in reduc-
ing testis weights and increasing uterine
weights in rats exposed pre- and postnatally
at concentrations 1–2 orders of magnitude
greater than concentrations reported for
human milk. It is unknown whether PCB
mixtures could produce similar effects in
nursing infants at the concentrations reported
for human milk. It also remains to be assessed
whether those effects would be manifested in
mixtures with other chemicals in human milk
that might be estrogenic, antiandrogenic, or
antiestrogenic, such as endogenous hormones.
Assessing mixture components. The alterna-
tive method of assessing mixtures, the compo-
nent approach, is to predict the toxicity of the
whole mixture from toxicity data on the indi-
vidual components of the mixture, including
any known pharmacokinetic or pharmaco-
dynamic interactions between those compo-
nents. The chief advantage of this approach, at
least in theory, is that the results can be used to
predict the effects of various mixtures. One sig-
niﬁcant disadvantage is the technical challenge
of designing and interpreting interaction stud-
ies for use in risk assessments (Borgert et al.
2001; U.S. EPA 1988). Failure to negotiate
those technical challenges renders much of the
literature on interactions inappropriate for use
in mixture risk assessment (Borgert et al. 2001;
U.S. EPA 1988).
The prototype model for component-
based mixture risk assessment for chemicals
with the same mechanism of toxicity is the
TEF/TEQ approach (Safe 1990). Here, the
toxicity of the whole mixture, expressed as
TEQs, is estimated from the concentration of
each component of the mixture multiplied by
its toxic equivalency factor (TEF), i.e., its rela-
tive potency factor (Safe 1998). This approach
assumes several toxicologic characteristics of
mixture components, including a) that the
individual chemicals all act through the same
biologic or toxic pathway; b) that the effects
of individual congeners in a mixture are dose
additive at submaximal levels of exposure
(i.e., that there is constant proportionality
between the toxicity of the components such
that their dose–response curves are parallel);
and c) that the toxic manifestations of all con-
geners are identical over the relevant range of
doses (Safe 1998).
Safe (1998) has enumerated the problems
with applying the TEQ approach to environ-
mental endocrine disruptors. Xenoestrogens are
a structurally diverse set of chemicals and, as
such, lack the similarities shared by true con-
geners. Uptake, distribution, and metabolism
of xenoestrogens can vary considerably, making
in vitro estimates of potency difﬁcult to extrap-
olate to intact animals. The development of a
TEF for estrogenicity is particularly hampered
by three recent developments, as noted previ-
ously. A second form of the ER has been identi-
ﬁed (Chang and Prins 1999; Gustafsson 2000;
Kuiper et al. 1996), and the two forms of ER
are activated differentially by some phytoestro-
gens and industrial chemicals (Kuiper et al.
1998); cross-talk occurs among signaling path-
ways for different hormones (Safe 1998), and
both genomic and nongenomic pathways ofReview | Assessing estrogenic potency of human milk
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estrogen modulation are signiﬁcant in estrogen-
responsive cells (DuMond et al. 2001). Thus,
estrogenic responses are a complex integration
of cell signaling via two ER receptor subtypes,
genomic and nongenomic pathways, and cross-
talk with other hormone-signaling pathways
(DuMond et al. 2001; Makela et al. 2000; Safe
1998) rather than deriving from a single bio-
logic pathway as required for application of a
TEF/TEQ approach.
Furthermore, the TEF/TEQ approach
assumes a dose-additive model for mixtures of
chemicals, but nonadditive interactions have
been reported for some combinations of xeno-
estrogens. Both greater-than-additive (e.g.,
Arnold et al. 1997; Bergeron et al. 1994) and
less-than-additive (McMurry and Dickerson
2001; Thorpe et al. 2001) effects have been
reported, although there is some concern regard-
ing the methods used to infer greater-than-
additive effects (Borgert et al. 2001). Although
few toxicologic interactions have been con-
ﬁrmed in animals exposed to concentrations of
putative estrogenic chemicals reported in human
milk, neither have dose-additive estrogenic
effects been demonstrated. Before an estrogenic
equivalence approach could be supported scien-
tiﬁcally, dose additivity would need to be veri-
ﬁed experimentally. Experimental veriﬁcation
would seem to be particularly important given
the potential for exogenous chemicals to act by
diverse hormonal mechanisms, as described
previously in this paper.
One approach that has not, to our knowl-
edge, been proposed in the literature is a non-
interaction model for xenoestrogens based on
statistical independence, sometimes called
“response additivity.” In such a model, each
chemical behaves as if other chemicals in the
mixture were not present (Bliss 1939; Finney
1971). Thus, independence models would
predict no response when all mixture compo-
nents are present at subthreshold concentra-
tions. Independence models may need to be
considered for exogenous estrogenic chemi-
cals, because those chemicals may operate via
independent estrogenic pathways at both the
molecular and cellular level, as discussed in
the previous section.
Of relevance to this discussion is a recent
study by Payne et al. (2001) in which the in
vitro estrogenic effects of a mixture of DDT
and its metabolites (essentially, technical-
grade DDT) could be modeled equally well
by dose-additive and independence models at
low concentrations. Because of the inherent
variability of biologic responses, it may often
be difficult to distinguish between these dif-
ferent no-interaction models at low chemical
concentrations. Because testing metabolites of
a chemical is similar to testing multiple doses
of the parent compound, one would have
expected dose-additive results (Finney 1971;
U.S. EPA 2000). This example, therefore,
underscores the complexity by which chemi-
cals can produce estrogenic responses, and it
must be kept in mind that metabolites of a
chemical may be estrogenic, but possibly via
mechanisms different than that of the parent
compound. A more recent in vitro study by
the same group found dose-additive effects
for a mixture of estrogen active chemicals
(Silva et al. 2002). Nonetheless, a number of
additional criteria remain to be fulﬁlled before
a TEF approach could be considered for those
chemicals, including correlating in vitro
results with in vivo toxicity (Safe 1995, 1990;
Safe et al. 1998).
Finally, the tissue-speciﬁc nature of some
estrogenic responses further complicates assign-
ing a single hormonal potency to a chemical.
As alluded to earlier, the complexity of estro-
genic responses is well illustrated by the drug
tamoxifen, which can be antiestrogenic in
breast tissue depending on the presence of
endogenous estrogen and estrogenic in uterus,
blood LDL cholesterol, and bone (Witorsch
2000, 2002). Other exogenous chemicals
detected in human milk and in human adipose
tissue may also have differential effects that are
both dose and tissue dependent. Such effects
could be mediated through agonistic activity at
the AhR, through alteration of xenoestrogen
metabolism, or through alteration of ER-acti-
vation kinetics as occurs with TCDD (Safe
1998; Safe et al. 1998), and via cross-talk with
other cell-signaling pathways. In addition,
TCDD has been reported to potentiate some
systemic effects of some estrogens, including
endogenous estrogen (Petroff et al. 2000,
2001). Because of the complexities inherent in
discreetly categorizing the hormonal activity of
exogenous chemicals, it seems that risk assess-
ment methods based on relative potency esti-
mates will be inapplicable for comparing risks
of different infant nutrition sources.
Epidemiologic and Clinical
Studies Relevant to Infant
Nutrition
As described in this review, the state of the
science does not provide a reliable methodology
for predicting the relative estrogenicity of
endogenous and exogenous chemicals in
human milk or in infant formula. However,
this does not preclude an assessment of estro-
genic health effects from infant nutrition if
other sources of data are available. In fact, epi-
demiologic and clinical data on infants exposed
to different sources of nutrition are available
and can potentially provide direct evidence of
health effects. Though such studies are not
typically sufficient to elucidate mechanisms
underlying health outcomes in an exposed
population, these may nonetheless be infor-
mative regarding adverse estrogenic effects
in infants. Epidemiologic and clinical data
regarding potential estrogenic effects in adults
are also available on persistent organic chemi-
cals (for example, from the Seveso, Italy, acci-
dent) and phytoestrogens (e.g., Li et al. 1998)
and could be informative as well. Carefully
designed epidemiologic or clinical studies have
the advantage of producing data directly from
the population of interest and are therefore
more readily interpretable to clinicians, public
health ofﬁcials, and ultimately to the public.
A number of epidemiologic studies have
investigated risk factors for developing breast
cancer. Because breast cancer risk may be
affected by lifetime estrogen exposure, includ-
ing exposures early in life, being breast-fed as an
infant was among the factors evaluated in sev-
eral of those studies (reviewed in Potischman
and Troisi 1999). Four case–control studies
reported a protective effect of having been
breast-fed, whereas three others reported no
association, except that one of the larger of the
three studies found a protective effect for pre-
menopausal breast cancer only. Exposure to
human milk in infancy may be related to
reduced risk of premenopausal breast cancer,
but appears unimportant as a risk factor for
postmenopausal disease. Although the mecha-
nisms are unknown, the apparent protection
observed in those studies may presumably arise
from protective factors in the milk itself or from
detrimental factors in formula preparations fed
the comparison group (Potischman and Troisi
1999). Whether potential protective effects are
related to estrogenic or antiestrogenic activity of
human milk is at present unknown.
Clinical data currently available indicate a
health beneﬁt to offspring for 6 weeks of breast-
feeding. At present, there is no evidence that
infants breast-fed for more than 6 weeks suffer
more adverse health effects, hormonally medi-
ated or otherwise, than infants receiving infant
formulas or other sources of nutrition. Effects
similar to those observed following high-dose
exposure to potent estrogens—e.g., in utero
exposure to DES—to the best of our knowl-
edge, have not been associated with breast-feed-
ing or other sources of infant nutrition. Thus,
the epidemiologic and clinical studies con-
ducted to date suggest that breast-fed infants
suffer no adverse estrogen-related health effects.
Given that much of the data on breast-fed
infants was collected several decades ago when
levels of persistent contaminants in humans
were likely higher than at present, particularly
in countries such as the United States where
the use/release of many of these chemicals has
been banned or restricted (LaKind et al. 2001;
Westphal 1986), estrogenic risks to infants
from consumption of human milk should be
considered de minimis. Nonetheless, the infor-
mation is limited regarding hormone-related
health effects associated with exogenous and
endogenous hormonally active chemicals in
human milk. Available literature on exogenous
chemicals in human milk is complicated by theReview | Borgert et al.
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natural variations of endogenous hormones in
human milk.
Although clinical data are limited for
infants fed soy-based formulas, no ill effects
have been reported for these exposures other
than soy-induced goiter, which was resolved in
the 1960s with the introduction of iodine-
supplemented infant soy formulas (Chorazy et
al. 1995; Setchell et al. 1997; Whitten and
Naftolin 1998). A small study associated soy-
based infant formulas with autoimmune thy-
roid disease in children genetically predisposed
to develop the condition (Fitzpatrick 1998;
Fort et al. 1990). Essex (1996) notes that
pediatricians and pediatric endocrinologists
have not seen large numbers of infants with
feminization—one theoretical outcome from
high exposures to phytoestrogens such as
isoﬂavones—and overtly estrogenic responses
in infants consuming soy-based formulas have
not been reported (Whitten et al. 1995). This
is in contrast to reports of feminization of
male infants whose mothers were taking oral
contraceptives while nursing (Grosvenor et al.
1992), and breast enlargement in an 18-
month-old female breast-fed infant whose
mother had been using oral contraceptives
(Madhavapeddi and Ramachandran 1985). A
report of premature thelarche (early breast
enlargement without additional signs of sexual
development) in Puerto Rico noted that con-
sumption of soy-based formula was one of sev-
eral positive associations in 120 pairs of
children (Freni-Titulaer et al. 1986); others
included maternal history of ovarian cysts and
consumption of various meat products.
To our knowledge, the only study on
endocrinologic and reproductive outcomes in
young adults fed soy-based infant formula is
that of Strom et al. (2001), who conducted a
retrospective cohort study comparing 248
adults fed soy-based formula as infants with
563 adults fed cow’s milk formula as infants.
Strom et al. (2001) found no statistically signiﬁ-
cant differences between these two groups
(either men or women) for more than 30 out-
comes, except for the following: Women fed
soy-based formula had a slightly longer dura-
tion of menstrual bleeding (0.37 days) and
greater discomfort (borderline significantly
more common) associated with menstruation.
Pubertal maturation, menstrual and reproduc-
tive history, height and weight, and general
health were not different for the two groups.
Because only limited data have been published
on risks/benefits associated with these infant
exposures in spite of the fact that infants con-
suming soy-based formulas have some of the
highest exposures to estrogenic chemicals,
Sheehan (1998) has advocated expanded, long-
term research on populations of infants exposed
to soy-based infant formulas. Epidemiologic
data, such as data to be collected as part of the
Study of Estrogen Activity and Development
(CODA 2001) sponsored by the National
Institute of Environmental Health Sciences,
may be useful in determining the extent to
which various sources of infant nutrition may
be associated with negative or positive health
outcomes (Barrett 2002; Setchell et al. 1997;
Sheehan 1998).
Although epidemiologic and clinical studies
can potentially provide the most reliable data
for comparing estrogenic risks of infant nutri-
tion sources, such studies are themselves subject
to several limitations. First, reliability depends
on sufﬁcient resolving power to detect low-fre-
quency effects, and comparative risks are most
accurate when all data are derived from large,
well-designed studies. The quality and quantity
of epidemiologic and clinical data are varied for
sources of infant nutrition, especially for human
milk containing environmental chemicals,
making comparative risk assessment difﬁcult.
Ideally, infant health status and infant expo-
sures to estrogenic compounds from all sources,
including endogenous estrogens, should be
assessed simultaneously if the data are to be
used in comparative risk assessments. However,
few studies include a credible assessment of
both infant health status and infant exposures.
For example, numerous problems have been
identiﬁed in studies reporting on neurodevelop-
mental effects of prenatal and postnatal PCB
exposure (Schell et al. 2001). Epidemiologic
data often involve confounding exposures to
mixtures that may not reﬂect the chemical mix-
ture proﬁles typically found in the breast milk
of lactating mothers.
The basis for epidemiologic and clinical
approaches could be improved by simultane-
ously collecting data on health outcomes and
levels of infant exposure to both xenoestrogens
and, where applicable, to natural estrogens and
phytoestrogens (Setchell et al. 1997) as are pre-
sent in human milk and certain infant formu-
las. It will be equally important to measure
concentrations of xenoestrogens in human
milk as well as natural and nutritionally related
ﬂuctuations in levels of maternal hormones in
human milk, including interindividual varia-
tions in human milk content (LaKind and
Berlin 2002; LaKind et al. 2001; Safe 1998). It
will be critical for such studies to be prospec-
tive and hypothesis driven rather than surveil-
lance oriented. For example, the hypothesis
that a speciﬁc component or mixture of com-
ponents in human milk confers protection
against premenopausal breast cancer deserves
further investigation.
Conclusions
Comparative risk assessment of estrogenic risks
from infant nutrition sources is not easily
accomplished by toxicologic methods currently
available. This is consistent with the conclu-
sions of a recent Society of Toxicology expert
panel that addressed challenges to assessing the
toxicity of low-level environmental chemical
mixtures (Nilsson 2000; Teuschler et al.
2002). Health risk estimates and public health
recommendations should not be based on esti-
mates of estrogenic potency or estrogenic
effects at this time, because of the tremendous
uncertainties inherent in data interpretation
and the very real possibility of introducing
rather than mitigating perceived health risks to
infants. Equating the results of in vitro tests
(such as binding of anthropogenic compounds
to a hormone receptor) to toxic effects on
human endocrine systems is a speculative
approach; health end points should be consid-
ered in any evaluation of risk (Nilsson 2000).
In addition, tests developed to determine
whether a chemical is an endocrine disruptor
should be able to distinguish between chemi-
cals that cause changes in the endocrine sys-
tem, i.e., endocrine active, from those that
cause harmful effects, i.e., endocrine disruptive.
Mechanistic approaches have been used to
improve the pharmacotherapy of many diseases
and hold great promise for advancing human
health risk assessment as well. However, until
the complex mechanisms of estrogen action are
clearly understood in relationship to specific
adverse health effects, methods that evaluate
total health outcomes and risks (such as epi-
demiologic and clinical studies) would seem to
provide more useful information regarding the
potential risks to offspring of endocrine-
disruptive chemicals in breast milk or infant
formulas. To date, the available epidemiologic
data do not suggest an increased incidence of
any estrogen-related adverse effect in either
breast-fed or formula-fed infants. Although epi-
demiologic approaches suffer a number of limi-
tations, large populations are available for
further study using standardized methods.
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